Log in

NASDAQ:VRTXVertex Pharmaceuticals Competitors & Alternatives

$291.31
+0.21 (+0.07 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$289.63
Now: $291.31
$295.00
50-Day Range
$263.89
MA: $281.78
$295.80
52-Week Range
$165.23
Now: $291.31
$299.21
Volume1.34 million shs
Average Volume1.95 million shs
Market Capitalization$75.53 billion
P/E Ratio50.49
Dividend YieldN/A
Beta0.94

Competitors

Vertex Pharmaceuticals (NASDAQ:VRTX) Vs. AMGN, GILD, CELG, REGN, BIIB, and SGEN

Should you be buying VRTX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Vertex Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seattle Genetics (SGEN).

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90
Amgen$23.36 billion6.45$7.84 billion$14.8217.29

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals31.35%25.69%18.50%
Amgen32.03%90.75%15.44%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vertex Pharmaceuticals and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072112.79
Amgen1111602.54

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, indicating a potential downside of 2.43%. Amgen has a consensus target price of $246.08, indicating a potential downside of 3.97%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Institutional & Insider Ownership

93.4% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 75.8% of Amgen shares are held by institutional investors. 0.5% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Amgen on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90
Gilead Sciences$22.45 billion4.29$5.39 billion$6.1412.50

Gilead Sciences has higher revenue and earnings than Vertex Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals31.35%25.69%18.50%
Gilead Sciences21.84%35.44%12.84%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vertex Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072112.79
Gilead Sciences3151002.25

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, indicating a potential downside of 2.43%. Gilead Sciences has a consensus target price of $79.6538, indicating a potential upside of 3.77%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Vertex Pharmaceuticals.

Institutional & Insider Ownership

93.4% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 80.2% of Gilead Sciences shares are held by institutional investors. 0.5% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Gilead Sciences on 10 of the 15 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Celgene (NASDAQ:CELG) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Celgene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90
Celgene$15.28 billion5.04$4.05 billion$7.6114.22

Celgene has higher revenue and earnings than Vertex Pharmaceuticals. Celgene is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Celgene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals31.35%25.69%18.50%
Celgene34.63%78.15%18.54%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Celgene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072112.79
Celgene06002.00

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, suggesting a potential downside of 2.43%. Celgene has a consensus target price of $105.60, suggesting a potential downside of 2.44%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Celgene.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Celgene has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Institutional and Insider Ownership

93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of Celgene shares are owned by institutional investors. 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Celgene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Celgene on 8 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Regeneron Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0131312.56
Vertex Pharmaceuticals072112.79

Regeneron Pharmaceuticals presently has a consensus target price of $557.7037, suggesting a potential downside of 11.09%. Vertex Pharmaceuticals has a consensus target price of $284.2308, suggesting a potential downside of 2.43%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Insider & Institutional Ownership

68.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.3% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals28.56%24.94%18.81%
Vertex Pharmaceuticals31.35%25.69%18.50%

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Biogen and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion3.01$5.89 billion$33.577.90
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90

Biogen has higher revenue and earnings than Vertex Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen40.76%49.22%24.26%
Vertex Pharmaceuticals31.35%25.69%18.50%

Insider & Institutional Ownership

87.5% of Biogen shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Biogen has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Biogen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen517902.13
Vertex Pharmaceuticals072112.79

Biogen presently has a consensus target price of $308.7037, suggesting a potential upside of 16.44%. Vertex Pharmaceuticals has a consensus target price of $284.2308, suggesting a potential downside of 2.43%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Vertex Pharmaceuticals.

Summary

Biogen beats Vertex Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seattle Genetics (NASDAQ:SGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

94.3% of Seattle Genetics shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 31.1% of Seattle Genetics shares are owned by company insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Seattle Genetics and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seattle Genetics$916.71 million32.19$-158,650,000.00($1.33)-128.16
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90

Vertex Pharmaceuticals has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Seattle Genetics and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seattle Genetics171212.62
Vertex Pharmaceuticals072112.79

Seattle Genetics presently has a consensus price target of $148.2778, suggesting a potential downside of 13.01%. Vertex Pharmaceuticals has a consensus price target of $284.2308, suggesting a potential downside of 2.43%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Seattle Genetics.

Profitability

This table compares Seattle Genetics and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seattle Genetics-32.81%-16.51%-13.88%
Vertex Pharmaceuticals31.35%25.69%18.50%

Risk & Volatility

Seattle Genetics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Seattle Genetics on 10 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.2$256.25+0.8%$151.91 billion$23.36 billion20.08
Gilead Sciences logo
GILD
Gilead Sciences
2.0$76.76+0.5%$95.77 billion$22.45 billion19.73
Celgene logo
CELG
Celgene
1.7$108.24+0.0%$77.04 billion$15.28 billion14.22
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$627.25+0.8%$68.48 billion$7.86 billion31.52Increase in Short Interest
Heavy News Reporting
Biogen logo
BIIB
Biogen
1.9$265.12+0.1%$43.26 billion$14.38 billion8.18Analyst Report
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$170.45+0.8%$29.26 billion$916.71 million-90.66
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$113.57+1.1%$24.80 billion$4.99 billion10.69
Incyte logo
INCY
Incyte
1.4$107.79+1.2%$23.50 billion$2.16 billion-61.59
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$127.71+0.7%$22.93 billion$1.70 billion209.36Analyst Report
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$152.43+1.7%$17.43 billion$219.75 million-18.98
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$89.01+2.6%$12.99 billion$876.29 million-114.12
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$127.66+1.8%$11.64 billion$788.10 million69.38
Immunomedics logo
IMMU
Immunomedics
1.9$40.63+7.6%$8.67 billion$290,000.00-22.20Analyst Report
Heavy News Reporting
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$60.78+0.0%$8.50 billion$1.12 billion55.25
Exelixis logo
EXEL
Exelixis
1.9$23.48+0.1%$7.18 billion$967.78 million25.25Increase in Short Interest
Repligen logo
RGEN
Repligen
1.2$126.59+0.0%$6.62 billion$270.24 million281.32Decrease in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.7$119.04+1.1%$5.30 billion$1.45 billion9.93Analyst Downgrade
Novavax logo
NVAX
Novavax
1.2$79.44+2.8%$4.73 billion$18.66 million-19.19
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.2$85.77+2.0%$4.47 billion$1.11 billion65.98Heavy News Reporting
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.55+0.3%$4.07 billion$182.24 million-11.96Insider Selling
Heavy News Reporting
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.6$27.99+1.9%$3.87 billion$195.99 million-50.89
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$32.94+2.0%$3.80 billion$23.87 million-11.76
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$57.84+0.3%$3.59 billion$36.13 million-53.06Unusual Options Activity
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.51+0.6%$3.18 billion$806.43 million-9.83
Alkermes logo
ALKS
Alkermes
1.1$19.59+0.9%$3.11 billion$1.17 billion-22.26
Opko Health logo
OPK
Opko Health
1.7$3.76+5.9%$2.37 billion$901.90 million-7.83Increase in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$113.82+1.9%$1.79 billion$120.28 million-33.09
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$109.37+2.0%$1.72 billionN/A-16.06
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.18+0.1%$1.62 billion$428.41 million19.21
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$46.10+2.1%$1.59 billion$252 million-4.30High Trading Volume
Innoviva logo
INVA
Innoviva
0.9$13.80+1.4%$1.41 billion$261.02 million8.07
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.4$9.63+2.6%$1.36 billion$102.43 million-11.60
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$4.95+1.4%$885.53 million$48.83 million-5.27Analyst Report
Heavy News Reporting
Myriad Genetics logo
MYGN
Myriad Genetics
1.4$11.58+2.8%$863.41 million$851.10 million-5.79Increase in Short Interest
Heavy News Reporting
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.89+0.2%$851.10 million$82.27 million-8.43
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.47+2.4%$799.24 million$35.22 million-4.60
Codexis logo
CDXS
Codexis
1.5$12.39+2.6%$712.37 million$68.46 million-49.56
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.23+0.3%$705.01 million$150,000.00-4.61
Agenus logo
AGEN
Agenus
1.5$3.96+1.5%$672.87 million$150.05 million-3.19
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.85+0.7%$646.42 million$227.19 million5.54Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
1.6$13.88+2.7%$617.82 million$22.27 million-6.40Analyst Downgrade
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.53+1.2%$508.31 million$143.01 million-0.91
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.9$62.31+0.2%$458.16 million$38.19 million18.71
Geron logo
GERN
Geron
1.2$2.13+1.9%$441.20 million$460,000.00-5.46
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.53+2.8%$399.49 million$109.33 million-2.94
MannKind logo
MNKD
MannKind
1.9$1.74+2.9%$381.52 million$63.04 million-7.57Analyst Downgrade
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10+0.0%$355.05 million$34.99 million-5.32
PDL BioPharma logo
PDLI
PDL BioPharma
1.0$2.91+2.4%$339.15 million$54.76 million-3.10
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$1.92+0.5%$323.65 million$59.29 million-12.00
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.9$12.61+1.4%$284.48 million$3.57 million-4.26Analyst Upgrade
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.